# US 2012/0255044 A1 · Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0255044 A1
- Document ID: US20120255044A1
- Status: Published application
- Kind: A1
- Application number: 13/379,346
- Filed: 2010-06-22
- Published: 2012-10-04
- Earliest claimed: 2009-06-22
- Assignees: The University of Tokyo
- Inventors: Hirotaka Matsuo; Nariyoshi Shinomiya; Takahiro Nakamura; Tappei Takada; Hiroshi Suzuki; Yuki Ikebuchi; Kousei Ito; Kimiyoshi Ichida
- Web page: https://patentgrep.com/patent/US20120255044A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/34: Genitourinary disorders
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

## Claims

### Claim 1

A urate transporter characterized in that it is formed from an ABCG2 protein and is capable of selectively and ATP-dependently exporting urate.

### Claim 2

A method for evaluating urate transport-related disease factor and inflammation-related disease factor, the method comprising:
evaluating whether or not a subject has a factor that induces urate transport failure, or a state or disease attributable to that failure, the method evaluating comprising: including detecting variations in genes that encode an ABCG2 protein using a sample containing human genes of the subject.

### Claim 3 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, wherein the detecting of variations in genes that encode an ABCG2 protein includes detecting an SNP or a gene polymorphism having a relationship of linkage disequilibrium with the SNP.

### Claim 4 (depends on 3)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor according to claim 3, wherein any one of a direct sequencing method, a BAC array CGH method, a FISH method, an RFLP method, a PCR-SSCP method, an allele-specific oligonucleotide hybridization method, a TaqMan PCR method, an invader method, an HRM method, a SmartAmp method, a Q-probe method (QP method), a MALDI-TOF/MS method, a molecular beacon method, an RCA method, a UCAN method, and a nucleic acid hybridization method using a DNA chip or a DNA microarray is used for the detection of a gene polymorphism.

### Claim 5 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, wherein, the detecting includes identifying an SNP producing at least one amino acid variation of a component selected from the group consisting of V12M, R113X, Q126X, Q141 K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and C608X as a as a factor in the inducement of urate transport failure, or a state or disease attributable to that failure.

### Claim 6 (depends on 5)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 5, wherein the detecting includes identifying an SNP producing either amino acid variation of Q126X alone or a combination of Q126X and Q141K as a factor in the inducement of urate transport failure, or a state or disease attributable to that failure.

### Claim 7 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, wherein the detecting includes identifying a functional change of ABCG2 including a functional failure thereof, as a factor in the inducement of urate transport failure, or a state or disease attributable to that failure.

### Claim 8 (depends on 7)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 7, wherein the functional change of ABCG2, including a functional failure thereof, comprises any one of
a functional change of ABCG2 by a gene variation other than the amino acid variations of an SNP producing at least one amino acid variation of a component selected from the group consisting of V12M, R113X, Q126X, Q141 K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and C608X,
a functional change of ABCG2 based on a change of an expression amount by a gene variation in exons or introns containing a promoter and an untranslated region (UTR) of ABCG2,
a functional change of ABCG2 by a change of a control factor including a transcription factor, or a compound,
a functional change of ABCG2 by a copy number variant (CNV),
an epigenetic change including DNA methylation, a functional change of ABCG2 by an RNA including a micro RNA or a noncoding RNA, and
a functional change of ABCG2 by a change of a stabilization mechanism of the ABCG2 protein.

### Claim 9 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, wherein, the detecting includes identifying a serum uric acid level as a state or disease attributable to urate transport failure.

### Claim 10 (depends on 9)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 9, wherein the serum uric acid level ranges between 6.0 and 9.0 mg/dl.

### Claim 11 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, the urate transport failure, or state or disease attributable to that failure, includes a hyperuricemia selected from a group consisting of a uric acid overproduction type, an extrarenal uric acid underexcretion type, a renal uric acid underexcretion type, and a mixed type thereof.

### Claim 12 (depends on 2)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 2, wherein the urate transport failure, or state or disease attributable to that failure, includes hyperuricemia, gout, rheumatoid arthritis, osteoarthritis, infertility, cerebral stroke, an ischemic heart disease, arrhythmia, photosensitivity, and a chronic kidney disease.

### Claim 13

An evaluation kit for urate transport-related disease factor and inflammation-related disease factor in a subject, the kit comprising a means for detecting a nucleic acid component that includes:
at least one SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, or C608X in an ABCG2 gene, or
a gene polymorphism having a relationship of linkage disequilibrium with the SNP,
wherein, the detecting includes using a sample containing human genes of the subject.

### Claim 14

A test sample for examining urate transport kinetics, comprising:
a nonhuman animal having a deficiency of an ABCG2 gene,
a nonhuman animal overexpressing a human or non-human ABCG2 gene,
a nonhuman animal overexpressing a human or non-human ABCG2 gene containing at least one variation of V12M, R113X, Q126X, Q141 K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, or C608X,
a nonhuman cell line or human cell line having a deficiency of an ABCG2 gene,
a nonhuman cell line or human cell line overexpressing a human or non-human ABCG2 gene,
a nonhuman cell line or human cell line overexpressing a human or non-human ABCG2 gene containing at least one variation of V12M, R113X, Q126X, Q141 K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, or C608X, or
a cell membrane vesicle prepared from these cell lines.

### Claim 15 (depends on 14)

The test sample of claim 14, comprising a mouse for examining urate transport kinetics, and the mouse is produced using a feedstuff containing oxonate as an inhibitor of urate-metabolizing enzyme uricase.

### Claim 16 (depends on 1)

A drug for urate transport-related diseases and inflammation-related diseases, which is a drug for reducing a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure, characterized in that:
it contains a polynucleotide encoding a urate transporter of claim 1 in the form capable of introducing it into cells.

### Claim 17 (depends on 9)

The method for evaluating urate transport-related disease factor and inflammation-related disease factor of claim 9, wherein the serum uric acid level ranges between 7.0 and 8.0 mg/dl.

### Claim 18 (depends on 15)

The test sample of claim 15, wherein the mouse a deficiency of an ABCG2 gene.

### Claim 19 (depends on 15)

The test sample of claim 15, wherein the mouse overexpresses an ABCG2 gene.

### Claim 20 (depends on 15)

The test sample of claim 15, wherein the mouse overexpresses an ABCG2 gene containing at least one variation of V12M, R113X, Q126X, Q141 K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, or C608X
